This report investigates current trends and opportunities affecting decisions on whether or not to outsource drug discovery. Outsourcing to low cost offshore destinations such as China and India are examined in detail. The report also covers a variety of strategic collaborations, academic partnerships and outsourcing opportunities along with case studies.
Features and benefits
* Develop an informed perspective of the drug discovery process including the role of outsourcing.* Understand the pros and cons of drug discovery outsourcing.* Gain an understanding of the current trends and opportunities in global drug discovery outsourcing market.* Compare the leading ten drug discovery service provider’s strategies and capabilities.* Assess China and India as drug discovery outsourcing destinations.
Highlights
As pharma companies relax their conservatism towards drug discovery outsourcing the market, which was valued at $7.4bn in 2009 is expected to increase to $18.5bn by 2015.Among discovery outsourcing serivces, chemistry services represented the leading category of outsourced drug discovery services generating around $2.9bn in sales, accounting for a market share of 39%. Biological services accounted for $2bn with a market share of 28%, which is expected to increase in the future.The networked pharma model under which companies reduce their footprint of owned facilities in favour of a network of service providers is gaining ground. Virtual companies which outsource almost all research, manufacturing and sales activities are also expected to drive growth in the drug discovery outsourcing market.
Your key questions answered
* What are the recent trends and opportunities in global drug discovery outsourcing market?* How will drug discovery outsourcing develop in the coming five years?* Which companies will drive the future of global drug discovery outsourcing market?* How is the drug discovery outsourcing market evolving in China and India?* What drug discovery outsourcing strategies are the leading pharmaceutical and biotech companies following?
Executive Summary
Introduction to drug discovery
The contract drug discovery market
Competitive landscape of the global drug discovery outsourcing market
Strategies for drug discovery outsourcing
About the author
Disclaimer
Introduction to drug discovery
Summary
Introduction
The drug discovery process
Identifying disease targets
Validation of the target
Assay development and screening process
Lead optimization
The role of CROs in drug discovery
The contract drug discovery market
Summary
Pros and cons of drug discovery outsourcing
Pros of outsourcing drug discovery
Cons of outsourcing drug discovery
Key industry trends
From transactional to strategic outsourcing
R&D restructuring in big pharma to create better opportunities for discovery CROs
Divestiture of drug discovery assets to reduce fixed costs
The Asia-Pacific region as an emerging location for drug discovery outsourcing
Rising consolidation in the drug discovery space
Impact of advances in genomics and pharmacogenomics
ADMET studies are a strong growth opportunity for drug discovery CROs
The drug discovery outsourcing market
Market forecast
Description of drug discovery technologies
Drug design
High-throughput screening (HTS)
ADMET
Combinatorial chemistry
Microfluidics (lab-on-a-chip)
Drug discovery outsourcing to Asia – a continuing phenomenon
Drug discovery outsourcing to China: an overview
Competitive landscape
Drug discovery outsourcing to India: an overview
Competitive landscape
Competitive landscape of global drug discovery outsourcing market
Summary
Introduction
Competitive landscape
Role of academics in drug discovery
Capability analysis of key drug discovery outsourcing companies
Company profiles
Albany Molecular Research (AMRI)
Asinex
BioDuro
Bridge Laboratories
Caliper Life Sciences
Charles River Laboratories (CRL)
Covance
Evotec
Ricerca Biosciences
WuXi AppTec
Strategies for drug discovery outsourcing
Summary
Introduction
Strategic outsourcing for greater flexibility and better efficiency
Consolidation in the drug discovery CRO industry for greater competitiveness
The "virtual pharma" model is expected to create greater opportunity for discovery CROs
The evolving networked R&D model to become more popular in the future
Selected case-studies
Wyeth and GVK Bio’s drug discovery alliance
Lilly and Covance’s R&D outsourcing deal
AstraZeneca and WuXi AppTec’s HTS outsourcing alliance
Hutchison MediPharma and Lilly, Merck KGaA and Procter & Gamble
Ranbaxy and GSK’s drug discovery deal
Nicholas Piramal India Ltd/Lilly and Merck & Co.
Bristol-Myers Squibb’s research center in Bangalore with Syngene
Appendix
Scope
Methodology
References
Abbreviations
Other selected research from the 'Business Development' category:
Deals and alliances in gastrointestinal diseases
Partneringdesk Amgen, Inc. and Company Deals Briefing
Other selected research from the 'Drug Discovery' category:
Opportunities in Stem Cell Research and Commercialization: Technology advances, regulatory impact and key players
Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress
Other selected research from the 'R&D' category:
The Drug Discovery Outsourcing Market
IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2012